Randomized non-inferiority clinical trial to evaluate the efficacy of a single fixed dose of 18 mg ivermectin for the treatment of uncomplicated strongyloidiasis

Start Date14 Sep 2023

Sponsor / Collaborator

Fundacio Hospital Universitari Vall d'Hebron-Institut de

NCT06434753

/ RecruitingPhase 3IIT

Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease: A Multicenter, Randomized, Double-blind, Placebo Controlled Clinical Trial

Zinc homeostasis could play a role in advanced chronic liver disease (cACLD) and its supplementation has been linked with improvement in liver function, decrease of hepatic complications and reduction in hepatocellular carcinoma (HCC) incidence. cACLD encompasses a heterogeneous group of patients with a variable risk of clinically significant portal hypertension (CSPH) and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that the administration of zinc can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death and liver transplantation). This study protocol describes an ongoing phase III, national, multicentre, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimal duration of follow up of 2 years. Our principal hypothesis is that zinc could modify the natural history of cACLD patients, with an overall improvement in prognosis

Start Date02 Oct 2022

Sponsor / Collaborator

Fundacio Hospital Universitari Vall d'Hebron-Institut de

[+7]

EUCTR2022-000617-13-ES

/ Not yet recruitingPhase 4IIT

A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific seroconversion after a fourth dose of SARS-CoV-2 mRNA vaccine in unresponsive Solid Organ Transplant recipients - TOR-VAX

Start Date12 Apr 2022

Sponsor / Collaborator

Fundacio Hospital Universitari Vall d'Hebron-Institut de

100 Clinical Results associated with Fundacio Hospital Universitari Vall d'Hebron-Institut de

0 Patents (Medical) associated with Fundacio Hospital Universitari Vall d'Hebron-Institut de

Literatures (Medical) associated with Fundacio Hospital Universitari Vall d'Hebron-Institut de

01 Apr 2025·Medicina Intensiva (English Edition)

Vasoactive-Inotropic Score in Takotsubo syndrome induced cardiogenic shock

Article

Author: Salamanca, Jorge ; Vila-Sanjuán, Sofía ; Martínez-Sellés, Manuel ; Uribarri, Aitor ; Ruiz-Ruiz, Julio ; Núñez-Gil, Iván J ; Blanco-Ponce, Emilia ; Almendro-Delia, Manuel ; Tomasino, Marco ; Martín, Agustín ; Vazirani, Ravi ; Corbí-Pascual, Miguel

OBJECTIVETo determine the prognostic value of the Vasoactive-Inotropic Score (VIS) in patients with Takotsubo syndrome (TTS) complicated by cardiogenic shock (CS).DESIGNRetrospective cohort analysis.SETTINGMulticenter registry (RETAKO) of patients diagnosed with TTS between 2003 and 2022.PATIENTS OR PARTICIPANTSA total of 1591 patients with TTS, of which 412 (26%) developed CS.INTERVENTIONSPatients were managed according to clinical criteria, with VIS calculated based on the maximum doses of inotropic and vasoactive drugs administered within the first 24 h of CS diagnosis.MAIN VARIABLES OF INTEREST30-day and 1-year mortality rates, VIS tertile classifications.RESULTSOf the patients who developed CS, 208 received inotropic support. Patients in the highest VIS tertile had significantly higher 30-day (HR 8.80, 95% CI 1.96-39.48; p = 0.005) and 1-year (HR 4.55, 95% CI 1.11-18.63; p < 0.035) mortality compared to the lowest tertile. High VIS was also linked to increased complications, including acute kidney injury, major bleeding, and the need for mechanical circulatory support. In-hospital mortality rates were 4% for the low tertile, 14% for the middle tertile, and 47% for the high tertile (p < 0.001).CONCLUSIONSVIS is associated with worse short- and long-term outcomes in TTS complicated by CS. Further research is needed to explore potential causal pathways, if any, and to optimize therapeutic strategies for these patients.

01 Feb 2025·Stroke

Abstract TP280: PREDICT-POOR_COMP: An artificial intelligence-based tool to predict poor medication compliance after stroke

Author: Ustrell, Xavier ; Silva, Yolanda ; Purroy, Francesc ; Olive-Gadea, Marta ; Paredes, Carolina Kina ; Rizzo, Federica ; Colangelo, Giorgio ; Rodriguez-Luna, David ; sanchez, Ester ; Simonetti, Renato ; Rodríguez Villatoro, Noelia ; Rubiera, Marta ; Pagola, Jorge ; Molina, Carlos ; Rodrigo Gisbert, Marc ; FREITAS, JOAO ; Muchada, Marian ; Marichal, Sebastian ; Ribo, Marc ; Garcia-Tornel Garcia-Camba, Alvaro ; Guirao, Cristina ; Cano, David ; Baladas, Maria

Background: Risk factor control and medication adherence are critical for stroke secondary prevention, but remain a significant challenge after discharge. We’ve developed an artificial intelligence (AI)-based algorithm to predict poor compliance to prescribed medication (PoorC-med) 90 days post-hospitalization. Methods: Consecutive stroke patients discharged from 5 comprehensive stroke centers followed by a multimodal holistic follow-up, including a mobile app for patient communication were evaluated. PoorC-med was defined by a score >0 on the Morisky Green scale. In-hospital and early follow-up multimodal variables were evaluated; those associated with PoorC-med (p<0.05 in the univariate analysis) were used to develop 2 logistic regression models, with variables available at 7 and 30 days after discharge. The models were optimized by grid search to maximize the F2 score, with 5-fold cross-validation to predict PoorC-med at 90 days. A subsequent pool of patients following the same protocol was used for external validation. Results: From January 1, 2020, 3261 patients were included in the multimodal follow-up; data on treatment compliance and >90 days follow-up were available for 1946 (59.7%). Of these, patients enrolled through September 23 (1801) were used to develop the AI algorithm; from October 2023, 145 patients were included in the validation set. Three hundred fifteen (17.5%) patients in the training and 33 (22.8%) in the validation set showed PoorC-med at 90 days. Variables associated with PoorC-med are shown in Fig.1. The logistic regression models (Fig. 2) showed the following performance on the training set: Confusion Matrix: [[549 937], [27 288]], Accuracy: 0.46, AUC: 0.64, F1 Score: 0.37, Recall: 0.91, Precision: 0.24, AUC PR: 0.36, AUROC: 0.72.The validation with an independent dataset yielded: Confusion Matrix: [[52 60], [3 30]], Accuracy: 0.57, AUC: 0.69, F1 Score: 0.49, Recall: 0.91, Precision: 0.33, AUC PR: 0.52, AUROC: 0.80 (Fig. 3). Predictions using variables available only 7 days after discharge showed: Accuracy 0.45, AUC 0.63, Recall 0.92, Precision 0.23, AUROC 0.66Conclusion: Our models are able to moderately predict poor medication compliance in stroke patients 90 days after discharge. Early identification of poorC-med patients may facilitate targeted interventions and improve secondary prevention. Further research is warranted to improve our performance and to translate the implementation of predictive models into clinical practice.

01 Dec 2024·Heart

Left ventricular outflow tract obstruction in Takotsubo syndrome with cardiogenic shock: prognosis and treatment

Article

Author: Vedia, Oscar ; Vila-Sanjuán, Sofía ; Martinez-Selles, Manuel ; Martin-Garcia, Agustin C ; Almendro-Delia, Manuel ; Becerra-Muñoz, Víctor Manuel ; Nuñez-Gil, Ivan Javier ; Corbi-Pascual, Miguel ; Blanco, Emilia ; Duran Cambra, Albert ; Guillén, Marta ; Pérez-Castellanos, Alberto ; Vazirani, Ravi ; Tomasino, Marco ; Reyes, Juan Albistur ; Fernández-Cordón, Clara ; Uribarri, Aitor ; Salamanca, Jorge

BackgroundPatients with Takotsubo syndrome (TTS) who develop cardiogenic shock may present with left ventricular outflow tract obstruction (LVOTO). The prognosis and treatment of this population have not been defined in previous studies. The aim of this study is to describe the clinical presentation, management, evolution and prognosis of a subgroup of patients with TTS and cardiogenic shock according to whether they present with LVOTO or not.MethodsWe analysed patients with TTS recruited from 2003 to 2022 in a multicentre registry. Patients were selected if they presented cardiogenic shock during their admission. This analysis was compared according to the presence or absence of LVOTO.Results322 patients were included, 58 (18%) of whom had LVOTO. The majority were treated with vasoactive and inotropic therapy (VIT) and its use was strongly associated with having LVOTO (77.6% vs 57.6%, p<0.001). Only five (3.3%) patients without LVOTO and two (4.4%) in the LVOTO group treated with VIT developed or worsened the obstruction. Furthermore, patients with LVOTO presented higher in-hospital complications including ventricular arrhythmias (15.5% vs 8.7%, p=0.017), major bleeding (13.8% vs 6.1%, p=0.042) and acute kidney failure (48.3% vs 28.4%, p=0.003). However, at both 90 days and 5 years, the cumulative incidence of all-cause death was not significantly different between the patients with and without LVOTO (HR 1.20, 95% CI 0.60 to 2.40 for 90 days, and HR 1.69, 95% CI 0.89 to 3.21 for 5 years).ConclusionsLVOTO is not uncommon in patients with TTS and cardiogenic shock. It is associated with a more aggressive in-hospital course and our data is unable to rule out an association between the presence of LVOTO and long-term prognosis of patients with TTS. The development or worsening of LVOTO directly related to inotropic or vasoactive support was low.

100 Deals associated with Fundacio Hospital Universitari Vall d'Hebron-Institut de

100 Translational Medicine associated with Fundacio Hospital Universitari Vall d'Hebron-Institut de

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 11 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Novel therapeutics for pediatric sarcoma (Oncoheroes Biosciences Inc)	Sarcoma More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis